Our Current Clinical Trials
We’re actively recruiting patients to participate in clinical trials to evaluate our therapeutic candidates. If you believe you or a loved one might be a good candidate for our trials, we encourage you to reach out directly via the link below.
Expanded Access Policy
INBRX-101 is a recombinant human AAT-Fc fusion protein therapeutic candidate currently being evaluated for the treatment of AATD. Early clinical data has demonstrated a promising pharmacokinetic profile that we believe supports a dosing schedule of every three to four weeks to achieve continuous normal AAT serum concentrations, a significant improvement from patients’ current regimen.
Inhibrx initiated a Phase 2 registration-enabling clinical trial for INBRX-101 using functional AAT as the primary endpoint for regulatory approval.
Learn more Phase 1 Trial Phase 2 Trial
INBRX-109
Our Tetravalent DR5 Agonist
INBRX-109 is a precisely engineered tetravalent sdAb-based therapeutic candidate that agonizes DR5 to induce tumor selective programmed cell death.
The Phase 1 trial for INBRX-109 is currently enrolling combination treatment cohorts in pancreatic adenocarcinoma, malignant pleural mesothelioma, Ewing sarcoma, and colorectal cancer.
The Phase 2 trial for INBRX-109 is currently enrolling patients with unresectable or metastatic conventional chondrosarcoma.
Learn more Phase 1 Trial Phase 2 Trial
INBRX-106
Our Hexavalent OX40 Agonist
INBRX-106 is a hexavalent sdAb-based therapeutic candidate targeting OX40, which is currently being evaluated in patients with locally advanced or metastatic solid tumors. Signaling through OX40 provides co-stimulation that promotes T-cell expansion, enhanced effector function and memory cell formation, and prevents activation-induced cell death.
Parts 2 and 4, single agent dose expansion and dose expansion in combination with Keytruda, are currently enrolling in the following tumor types:
- Solid Tumors
- Non-Small Cell Lung Cancer (NSCLC)
- Melanoma
- Head and Neck Cancer
- Gastric Cancer (GIST)
- Renal Cell Carcinoma (RCC)
- Urothelial Carcinoma
INBRX-105
Our PD-L1 x 4-1BB Tetravalent Conditional Agonist
INBRX-105 is a tetravalent sdAb-based therapeutic candidate that’s currently being evaluated in patients with programmed death ligand 1 (PD-L1) expressing tumors, including those refractory to, or relapsed from, approved checkpoint inhibitor therapies. INBRX-105 is designed to agonize 4-1BB selectively in the presence of PD-L1.
The Phase 1 trial for INBRX-105 completed Parts 1 and 3, single agent dose escalation and dose escalation in combination with Keytruda, and is currently enrolling Parts 2 and 4, single agent dose expansion and dose expansion in combination with Keytruda, in the following tumor types:
- Metastatic Solid Tumors
- Non-Small Cell Lung Cancer (NSCLC)
- Melanoma
- Head and Neck Squamous Cell Carcinoma
- Gastric Adenocarcinoma
- Renal Cell Carcinoma (RCC)
- Urothelial Carcinoma
- Esophageal Adenocarcinoma
